Jake G. Edmans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jake G. Edmans has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Craig Murdoch
School of Clinical Dentistry, University of Sheffield, Sheffield, United Kingdom
3 shared publications - Helen Elizabeth Colley
School of Clinical Dentistry, University of Sheffield, Sheffield, UK
3 shared publications Lars Siim Madsen
AFYX Therapeutics, Agern Alle 24, DK-2970 Hørsholm, Denmark
2 shared publications- Martin E. Santocildes-Romero
AFYX Therapeutics, Agern Alle 24, DK-2970 Hørsholm, Denmark
2 shared publications - Paul Vincent Hatton
School of Clinical Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield, S10 2TA, UK
2 shared publications - Asma El Howati
School of Clinical Dentistry, 19 Claremont Crescent, University of Sheffield, Sheffield, S10 2TA, United Kingdom; Department of Oral Medicine, Faculty of Dentistry, University of Benghazi, Benghazi, Libya
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
Combined electrospun fibre-microneedle patches for enhanced transmucosal delivery of benzodiazepines and proteins
A microneedle mucoadhesive patch composite enhances drug delivery to the oral mucosa.
- 27 May 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
Open AccessCombined electrospun fibre-microneedle patches for enhanced transmucosal delivery of benzodiazepines and proteins
A microneedle mucoadhesive patch composite enhances drug delivery to the oral mucosa.
- Open Access
- 3 October 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (6) , 1447-1458.e3
A Tissue-Engineered Model of T-Cell–Mediated Oral Mucosal Inflammatory Disease
- 3 October 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (6) , 1447-1458.e3
Open AccessA Tissue-Engineered Model of T-Cell–Mediated Oral Mucosal Inflammatory Disease
- Open Access
- 21 June 2023
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 2 (1) , 444-453
Bioactive Protein and Peptide Release from a Mucoadhesive Electrospun Membrane
Protein-based biologics constitute a rapidly expanding category of therapeutic agents with high target specificity. Their clinical use has dramatically increased in recent years, but administration is largely via injection. Drug delivery across the oral mucosa is a promising alternative to injections, in order to avoid the gastrointestinal tract and first-pass metabolism. Current drug delivery formulations include liquid sprays, mucoadhesive tablets and films, which lack dose control in the presence of salivary flow. To address this, electrospun membranes that adhere tightly to the oral mucosa and release drugs locally have been developed. Here, we investigated the suitability of these mucoadhesive membranes for peptide or protein release. Bradykinin (0.1%) or insulin (1, 3, and 5%) were incorporated by electrospinning from ethanol/water mixtures. Immersion of membranes in buffer resulted in the rapid release of bradykinin, with a maximal release of 70 ± 12% reached after 1 h. In contrast, insulin was liberated more slowly, with 88 ± 11, 69.0 ± 5.4, and 63.9 ± 9.0% cumulative release of the total encapsulated dose after 8 h for membranes containing 1, 3, and 5% w/w insulin, respectively. Membrane–eluted bradykinin retained pharmacological activity by inducing rapid intracellular calcium release upon binding to its cell surface receptor on oral fibroblasts, when examined by flow cytometry. To quantify further, time-lapse confocal microscopy revealed that membrane–eluted bradykinin caused a 1.58 ± 0.16 fold-change in intracellular calcium fluorescence after 10 s compared to bradykinin solution (2.13 ± 0.21), relative to placebo. In conclusion, these data show that electrospun membranes may be highly effective vehicles for site-specific administration of biotherapeutic proteins or peptides directly to the oral mucosa for either local or systemic drug delivery applications.
- 21 June 2023
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 2 (1) , 444-453
Open AccessBioactive Protein and Peptide Release from a Mucoadhesive Electrospun Membrane
Protein-based biologics constitute a rapidly expanding category of therapeutic agents with high target specificity. Their clinical use has dramatically increased in recent years, but administration is largely via injection. Drug delivery across the oral mucosa is a promising alternative to injections, in order to avoid the gastrointestinal tract and first-pass metabolism. Current drug delivery formulations include liquid sprays, mucoadhesive tablets and films, which lack dose control in the presence of salivary flow. To address this, electrospun membranes that adhere tightly to the oral mucosa and release drugs locally have been developed. Here, we investigated the suitability of these mucoadhesive membranes for peptide or protein release. Bradykinin (0.1%) or insulin (1, 3, and 5%) were incorporated by electrospinning from ethanol/water mixtures. Immersion of membranes in buffer resulted in the rapid release of bradykinin, with a maximal release of 70 ± 12% reached after 1 h. In contrast, insulin was liberated more slowly, with 88 ± 11, 69.0 ± 5.4, and 63.9 ± 9.0% cumulative release of the total encapsulated dose after 8 h for membranes containing 1, 3, and 5% w/w insulin, respectively. Membrane–eluted bradykinin retained pharmacological activity by inducing rapid intracellular calcium release upon binding to its cell surface receptor on oral fibroblasts, when examined by flow cytometry. To quantify further, time-lapse confocal microscopy revealed that membrane–eluted bradykinin caused a 1.58 ± 0.16 fold-change in intracellular calcium fluorescence after 10 s compared to bradykinin solution (2.13 ± 0.21), relative to placebo. In conclusion, these data show that electrospun membranes may be highly effective vehicles for site-specific administration of biotherapeutic proteins or peptides directly to the oral mucosa for either local or systemic drug delivery applications.